BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9240258)

  • 1. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome.
    Chen CD; Wu MY; Yang JH; Chen SU; Ho HN; Yang YS
    Fertil Steril; 1997 Aug; 68(2):287-91. PubMed ID: 9240258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome.
    Shaker AG; Zosmer A; Dean N; Bekir JS; Jacobs HS; Tan SL
    Fertil Steril; 1996 May; 65(5):992-6. PubMed ID: 8612863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study.
    Gokmen O; Ugur M; Ekin M; Keles G; Turan C; Oral H
    Eur J Obstet Gynecol Reprod Biol; 2001 Jun; 96(2):187-92. PubMed ID: 11384805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe ovarian hyperstimulation syndrome: is it really preventable by prophylactic intravenous albumin?
    Ndukwe G; Thornton S; Fishel S; Dowell K; Aloum M
    Fertil Steril; 1997 Nov; 68(5):851-4. PubMed ID: 9389814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study.
    Isik AZ; Gokmen O; Zeyneloglu HB; Kara S; Keles G; Gulekli B
    Eur J Obstet Gynecol Reprod Biol; 1996 Dec; 70(2):179-83. PubMed ID: 9119100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome.
    Chen CD; Chao KH; Yang JH; Chen SU; Ho HN; Yang YS
    Fertil Steril; 2003 Jul; 80(1):86-90. PubMed ID: 12849806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined approach as an effective method in the prevention of severe ovarian hyperstimulation syndrome.
    Isik AZ; Vicdan K
    Eur J Obstet Gynecol Reprod Biol; 2001 Aug; 97(2):208-12. PubMed ID: 11451550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study.
    Shoham Z; Weissman A; Barash A; Borenstein R; Schachter M; Insler V
    Fertil Steril; 1994 Jul; 62(1):137-42. PubMed ID: 8005278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant follicle-stimulating hormone in the treatment of patients with history of severe ovarian hyperstimulation syndrome.
    Aboulghar MA; Mansour RT; Serour GI; Amin YM; Sattar MA; elAttar E
    Fertil Steril; 1996 Nov; 66(5):757-60. PubMed ID: 8893680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited ovarian stimulation (LOS), prevents the recurrence of severe forms of ovarian hyperstimulation syndrome in polycystic ovarian disease.
    El-Sheikh MM; Hussein M; Fouad S; El-Sheikh R; Bauer O; Al-Hasani S
    Eur J Obstet Gynecol Reprod Biol; 2001 Feb; 94(2):245-9. PubMed ID: 11165733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: a prospective randomized study.
    Tan SL; Balen A; el Hussein E; Campbell S; Jacobs HS
    Fertil Steril; 1992 Aug; 58(2):378-83. PubMed ID: 1633906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of severe ovarian hyperstimulation by coasting.
    Dhont M; Van der Straeten F; De Sutter P
    Fertil Steril; 1998 Nov; 70(5):847-50. PubMed ID: 9806565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization.
    Sher G; Zouves C; Feinman M; Maassarani G
    Hum Reprod; 1995 Dec; 10(12):3107-9. PubMed ID: 8822423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study.
    Bellver J; Muñoz EA; Ballesteros A; Soares SR; Bosch E; Simón C; Pellicer A; Remohí J
    Hum Reprod; 2003 Nov; 18(11):2283-8. PubMed ID: 14585874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinction between early and late ovarian hyperstimulation syndrome.
    Mathur RS; Akande AV; Keay SD; Hunt LP; Jenkins JM
    Fertil Steril; 2000 May; 73(5):901-7. PubMed ID: 10785214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.